IDEX Corporation Reports 10.1% Revenue Growth in Q3 2025

IDEX Corporation reported a notable increase in its financial performance for the third quarter of 2025, with net sales reaching $878.7 million, up from $798.2 million in the same period last year, marking a 10.1% increase. The company's gross profit also rose to $390.6 million, compared to $353.9 million in the prior year, resulting in a gross margin of 44.4%. Operating income for the quarter was $185.8 million, slightly higher than the $168.0 million reported in Q3 2024. However, net income attributable to IDEX increased to $127.8 million, up from $119.1 million, reflecting a diluted earnings per share of $1.70, compared to $1.57 in the previous year.

In terms of year-to-date performance, IDEX reported net sales of $2.558 billion for the nine months ending September 30, 2025, a 6.3% increase from $2.406 billion in the same period of 2024. The company’s operating income for the nine months was $515.7 million, slightly up from $511.9 million, while net income attributable to IDEX decreased to $354.9 million from $381.8 million in the prior year. The decline in net income was attributed to increased interest expenses and restructuring costs, which totaled $18.3 million for the nine months, compared to $5.4 million in the same period last year.

Strategically, IDEX has been active in expanding its portfolio through acquisitions. In July 2025, the company acquired Micro-LAM, Inc. for $80.7 million, enhancing its capabilities in advanced optics manufacturing. This acquisition is expected to complement IDEX's existing offerings in the Health & Science Technologies segment. Additionally, the company has been focusing on restructuring initiatives aimed at improving operational efficiency, which included a reduction in headcount and the elimination of certain management layers. These changes are anticipated to be completed by the end of 2025.

Operationally, IDEX has seen growth in its customer base and product adoption rates. The Health & Science Technologies segment reported external sales of $380.1 million in Q3 2025, up from $309.9 million in Q3 2024, driven by increased demand for scientific fluidics and optics solutions. The Fluid & Metering Technologies segment also experienced growth, with sales rising to $316.8 million from $300.6 million. The company’s total employee headcount has remained stable, with a slight increase reflecting the integration of acquired businesses.

Looking ahead, IDEX remains cautiously optimistic about its future performance, despite potential macroeconomic challenges. The company anticipates continued growth in its core markets, supported by strategic acquisitions and ongoing productivity initiatives. However, management has acknowledged the impact of rising interest rates and inflation on operational costs, which may affect profitability in the near term. The company plans to maintain its focus on cost containment and efficiency improvements to navigate these challenges effectively.